{
    "info": {
        "nct_id": "NCT06699212",
        "official_title": "A Phase 3 Multicenter, Randomized, Open-label Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients With Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) With No Distant Metastases",
        "inclusion_criteria": "* Histological or cytological evidence of squamous cell carcinoma of a head and neck primary site (per American Joint Committee on Cancer [AJCC], other than nasopharynx or cuSCC).\n* Appropriate for SOC first-line treatment of their recurrent head and neck cancer with pembrolizumab ± chemotherapy.\n* No known history of any distant metastatic disease (M1 by AJCC eighth edition).\n* Tumors with at least one PIT-accessible and RECIST 1.1 measurable lesion as assessed by investigator.\n* Anti-PD-1 and anti-PD-L1-treatment naïve.\n* Combined positive score (CPS) ≥ 1 as determined locally by an FDA-approved test\n* Have results from testing of human papillomavirus (HPV) status for oropharyngeal cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at the time of screening\n* Adequate hematologic, renal, and hepatic organ function\n* Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and must be willing to use a highly effective birth control while on study or be surgically sterile or abstain from heterosexual sexual activity for the course of the study through 180 days after the last dose of study treatment. Male patients must agree to use a highly effective method of contraception starting with the first dose of study medication through 120 days after the last dose of study treatment.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Diagnosed and/or treated for additional malignancy within 2 years before randomization except for those with a negligible risk of metastasis or death (such as adequately treated carcinoma in situ of the cervix, basal cell skin cancer, localized prostate cancer, or ductal carcinoma in situ). Patients with a history of other prior cancer treated with complete surgical resection and with no evidence of disease may be eligible based on discussion with the Medical Monitor.\n* History of significant (Grade ≥ 3) cetuximab infusion reactions\n* Prior allogeneic tissue/solid organ transplant\n* Known or active central nervous system metastases and/or carcinomatous meningitis\n* Life expectancy of less than 3 months\n* Active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.\n* Evidence of interstitial lung disease or current active, noninfectious pneumonitis\n* Active infection requiring systemic therapies such as antibiotic, antifungal, or antiviral intervention\n* Known or active bacterial, viral, or fungal infection including tuberculosis, Hepatitis B (e.g., HBV DNA is detected), or Hepatitis C (e.g., RNA [qualitative] is detected)\n* Known history of testing positive for human immunodeficiency virus or acquired immunodeficiency syndrome (AIDS)-related illness\n* Prior or ongoing Grade ≥ 3 tumor hemorrhage within 12 weeks of randomization\n* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Prior systemic chemotherapy or targeted small molecule therapy or radiation therapy within 2 weeks of C1D1 or has not recovered (i.e., Grade ≤ 1 or at baseline) from adverse events (AEs) due to previously administered agent\n* Prior anticancer monoclonal antibody therapy or investigational agent or intervention within 4 weeks of C1D1 or has not recovered (i.e., Grade ≤ 1 or at baseline) from AEs due to previously administered agent\n* Prior receipt of ASP-1929 at any time\n* Receiving chronic systemic steroid therapy (in doses exceeding 10 mg per day of prednisone equivalent) or any other form of immunosuppressive therapy within 14 days prior to randomization\n* Received a live vaccine within 4 weeks of randomization; seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed\n* Requiring future examinations or treatments within 4 weeks after an ASP-1929 PIT treatment exposing the patient to significant light (e.g., eye examinations, surgical procedures, endoscopy) that is unrelated to the ASP-1929 PIT treatment\n* Major surgery or significant traumatic injury within 4 weeks before randomization, or anticipation of the need for major surgery during the course of study treatment",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Appropriate for SOC first-line treatment of their recurrent head and neck cancer with pembrolizumab ± chemotherapy.",
            "criterions": [
                {
                    "exact_snippets": "Appropriate for SOC first-line treatment of their recurrent head and neck cancer with pembrolizumab ± chemotherapy",
                    "criterion": "appropriateness for SOC first-line treatment with pembrolizumab ± chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "appropriateness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "recurrent head and neck cancer",
                    "criterion": "head and neck cancer",
                    "requirements": [
                        {
                            "requirement_type": "recurrence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histological or cytological evidence of squamous cell carcinoma of a head and neck primary site (per American Joint Committee on Cancer [AJCC], other than nasopharynx or cuSCC).",
            "criterions": [
                {
                    "exact_snippets": "Histological or cytological evidence of squamous cell carcinoma",
                    "criterion": "squamous cell carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "evidence type",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "of a head and neck primary site (per American Joint Committee on Cancer [AJCC]",
                    "criterion": "primary tumor site",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "head and neck"
                        }
                    ]
                },
                {
                    "exact_snippets": "other than nasopharynx or cuSCC",
                    "criterion": "primary tumor site exclusion",
                    "requirements": [
                        {
                            "requirement_type": "excluded locations",
                            "expected_value": [
                                "nasopharynx",
                                "cuSCC"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No known history of any distant metastatic disease (M1 by AJCC eighth edition).",
            "criterions": [
                {
                    "exact_snippets": "No known history of any distant metastatic disease (M1 by AJCC eighth edition)",
                    "criterion": "distant metastatic disease (M1 by AJCC eighth edition)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Anti-PD-1 and anti-PD-L1-treatment naïve.",
            "criterions": [
                {
                    "exact_snippets": "Anti-PD-1 and anti-PD-L1-treatment naïve",
                    "criterion": "anti-PD-1 treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": "naïve"
                        }
                    ]
                },
                {
                    "exact_snippets": "Anti-PD-1 and anti-PD-L1-treatment naïve",
                    "criterion": "anti-PD-L1 treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": "naïve"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumors with at least one PIT-accessible and RECIST 1.1 measurable lesion as assessed by investigator.",
            "criterions": [
                {
                    "exact_snippets": "Tumors with at least one PIT-accessible ... lesion",
                    "criterion": "tumor lesion",
                    "requirements": [
                        {
                            "requirement_type": "PIT-accessibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "RECIST 1.1 measurable lesion as assessed by investigator",
                    "criterion": "tumor lesion",
                    "requirements": [
                        {
                            "requirement_type": "RECIST 1.1 measurability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Combined positive score (CPS) ≥ 1 as determined locally by an FDA-approved test",
            "criterions": [
                {
                    "exact_snippets": "Combined positive score (CPS) ≥ 1",
                    "criterion": "Combined positive score (CPS)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have results from testing of human papillomavirus (HPV) status for oropharyngeal cancer",
            "criterions": [
                {
                    "exact_snippets": "results from testing of human papillomavirus (HPV) status for oropharyngeal cancer",
                    "criterion": "HPV status testing for oropharyngeal cancer",
                    "requirements": [
                        {
                            "requirement_type": "results_available",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at the time of screening",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at the time of screening",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematologic, renal, and hepatic organ function",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematologic ... organ function",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal ... organ function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... hepatic organ function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and must be willing to use a highly effective birth control while on study or be surgically sterile or abstain from heterosexual sexual activity for the course of the study through 180 days after the last dose of study treatment. Male patients must agree to use a highly effective method of contraception starting with the first dose of study medication through 120 days after the last dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP) ... must be willing to use a highly effective birth control while on study",
                    "criterion": "birth control use (WOCBP)",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "while on study"
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP) ... or be surgically sterile",
                    "criterion": "surgical sterility (WOCBP)",
                    "requirements": [
                        {
                            "requirement_type": "sterility status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP) ... or abstain from heterosexual sexual activity for the course of the study through 180 days after the last dose of study treatment",
                    "criterion": "sexual activity abstinence (WOCBP)",
                    "requirements": [
                        {
                            "requirement_type": "abstinence from heterosexual sexual activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "course of the study through 180 days after the last dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "Male patients must agree to use a highly effective method of contraception starting with the first dose of study medication through 120 days after the last dose of study treatment",
                    "criterion": "contraception use (male patients)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "starting with the first dose of study medication through 120 days after the last dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Prior receipt of ASP-1929 at any time",
            "criterions": [
                {
                    "exact_snippets": "Prior receipt of ASP-1929 at any time",
                    "criterion": "ASP-1929 receipt",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of less than 3 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of less than 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior systemic chemotherapy or targeted small molecule therapy or radiation therapy within 2 weeks of C1D1 or has not recovered (i.e., Grade ≤ 1 or at baseline) from adverse events (AEs) due to previously administered agent",
            "criterions": [
                {
                    "exact_snippets": "Prior systemic chemotherapy or targeted small molecule therapy or radiation therapy within 2 weeks of C1D1",
                    "criterion": "prior systemic chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior systemic chemotherapy or targeted small molecule therapy or radiation therapy within 2 weeks of C1D1",
                    "criterion": "prior targeted small molecule therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior systemic chemotherapy or targeted small molecule therapy or radiation therapy within 2 weeks of C1D1",
                    "criterion": "prior radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has not recovered (i.e., Grade ≤ 1 or at baseline) from adverse events (AEs) due to previously administered agent",
                    "criterion": "recovery from adverse events due to previously administered agent",
                    "requirements": [
                        {
                            "requirement_type": "severity of adverse events",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "recovery to baseline",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receiving chronic systemic steroid therapy (in doses exceeding 10 mg per day of prednisone equivalent) or any other form of immunosuppressive therapy within 14 days prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Receiving chronic systemic steroid therapy (in doses exceeding 10 mg per day of prednisone equivalent)",
                    "criterion": "chronic systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg per day of prednisone equivalent"
                            }
                        },
                        {
                            "requirement_type": "receiving",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any other form of immunosuppressive therapy within 14 days prior to randomization",
                    "criterion": "immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "receiving",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior anticancer monoclonal antibody therapy or investigational agent or intervention within 4 weeks of C1D1 or has not recovered (i.e., Grade ≤ 1 or at baseline) from AEs due to previously administered agent",
            "criterions": [
                {
                    "exact_snippets": "Prior anticancer monoclonal antibody therapy ... within 4 weeks of C1D1",
                    "criterion": "prior anticancer monoclonal antibody therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "investigational agent or intervention within 4 weeks of C1D1",
                    "criterion": "prior investigational agent or intervention",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has not recovered (i.e., Grade ≤ 1 or at baseline) from AEs due to previously administered agent",
                    "criterion": "adverse events due to previously administered agent",
                    "requirements": [
                        {
                            "requirement_type": "recovery from adverse events",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "adverse event grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery or significant traumatic injury within 4 weeks before randomization, or anticipation of the need for major surgery during the course of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Major surgery ... within 4 weeks before randomization",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "significant traumatic injury within 4 weeks before randomization",
                    "criterion": "significant traumatic injury",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of the need for major surgery during the course of study treatment",
                    "criterion": "anticipated need for major surgery",
                    "requirements": [
                        {
                            "requirement_type": "anticipated during study treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known or active bacterial, viral, or fungal infection including tuberculosis, Hepatitis B (e.g., HBV DNA is detected), or Hepatitis C (e.g., RNA [qualitative] is detected)",
            "criterions": [
                {
                    "exact_snippets": "Known or active bacterial ... infection",
                    "criterion": "bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known or active ... viral ... infection",
                    "criterion": "viral infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known or active ... fungal infection",
                    "criterion": "fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including tuberculosis",
                    "criterion": "tuberculosis infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hepatitis B (e.g., HBV DNA is detected)",
                    "criterion": "Hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "HBV DNA detection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hepatitis C (e.g., RNA [qualitative] is detected)",
                    "criterion": "Hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "HCV RNA detection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior or ongoing Grade ≥ 3 tumor hemorrhage within 12 weeks of randomization",
            "criterions": [
                {
                    "exact_snippets": "Prior or ongoing Grade ≥ 3 tumor hemorrhage within 12 weeks of randomization",
                    "criterion": "tumor hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior or ongoing within 12 weeks of randomization"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogeneic tissue/solid organ transplant",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic tissue/solid organ transplant",
                    "criterion": "allogeneic tissue transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior allogeneic tissue/solid organ transplant",
                    "criterion": "allogeneic solid organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosed and/or treated for additional malignancy within 2 years before randomization except for those with a negligible risk of metastasis or death (such as adequately treated carcinoma in situ of the cervix, basal cell skin cancer, localized prostate cancer, or ductal carcinoma in situ). Patients with a history of other prior cancer treated with complete surgical resection and with no evidence of disease may be eligible based on discussion with the Medical Monitor.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosed and/or treated for additional malignancy within 2 years before randomization",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis or treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years before randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for those with a negligible risk of metastasis or death (such as adequately treated carcinoma in situ of the cervix, basal cell skin cancer, localized prostate cancer, or ductal carcinoma in situ)",
                    "criterion": "additional malignancy risk",
                    "requirements": [
                        {
                            "requirement_type": "risk of metastasis or death",
                            "expected_value": "negligible"
                        },
                        {
                            "requirement_type": "examples",
                            "expected_value": [
                                "adequately treated carcinoma in situ of the cervix",
                                "basal cell skin cancer",
                                "localized prostate cancer",
                                "ductal carcinoma in situ"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with a history of other prior cancer treated with complete surgical resection and with no evidence of disease may be eligible based on discussion with the Medical Monitor.",
                    "criterion": "history of other prior cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": "complete surgical resection"
                        },
                        {
                            "requirement_type": "evidence of disease",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "eligibility determination",
                            "expected_value": "discussion with Medical Monitor"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known or active central nervous system metastases and/or carcinomatous meningitis",
            "criterions": [
                {
                    "exact_snippets": "Known or active central nervous system metastases",
                    "criterion": "central nervous system metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled intercurrent illness including, but not limited to, ... unstable angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled intercurrent illness including, but not limited to, ... cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness/social situations that would limit compliance with study requirements",
                    "criterion": "psychiatric illness or social situations",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received a live vaccine within 4 weeks of randomization; seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed",
            "criterions": [
                {
                    "exact_snippets": "Received a live vaccine within 4 weeks of randomization",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed",
                    "criterion": "seasonal influenza vaccine for injection",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "inactivated"
                        },
                        {
                            "requirement_type": "route of administration",
                            "expected_value": "injection"
                        },
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed",
                    "criterion": "intranasal influenza vaccine",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "live attenuated"
                        },
                        {
                            "requirement_type": "route of administration",
                            "expected_value": "intranasal"
                        },
                        {
                            "requirement_type": "allowance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of testing positive for human immunodeficiency virus or acquired immunodeficiency syndrome (AIDS)-related illness",
            "criterions": [
                {
                    "exact_snippets": "Known history of testing positive for human immunodeficiency virus",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history of positive test",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "acquired immunodeficiency syndrome (AIDS)-related illness",
                    "criterion": "AIDS-related illness",
                    "requirements": [
                        {
                            "requirement_type": "history of diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of interstitial lung disease or current active, noninfectious pneumonitis",
            "criterions": [
                {
                    "exact_snippets": "Evidence of interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "current active, noninfectious pneumonitis",
                    "criterion": "noninfectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "current active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs)",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic treatment time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment",
                    "criterion": "replacement therapy",
                    "requirements": [
                        {
                            "requirement_type": "considered systemic treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of significant (Grade ≥ 3) cetuximab infusion reactions",
            "criterions": [
                {
                    "exact_snippets": "History of significant (Grade ≥ 3) cetuximab infusion reactions",
                    "criterion": "cetuximab infusion reactions",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection requiring systemic therapies such as antibiotic, antifungal, or antiviral intervention",
            "criterions": [
                {
                    "exact_snippets": "Active infection requiring systemic therapies",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": "systemic therapies"
                        }
                    ]
                },
                {
                    "exact_snippets": "systemic therapies such as antibiotic, antifungal, or antiviral intervention",
                    "criterion": "systemic therapy type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "antibiotic",
                                "antifungal",
                                "antiviral"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requiring future examinations or treatments within 4 weeks after an ASP-1929 PIT treatment exposing the patient to significant light (e.g., eye examinations, surgical procedures, endoscopy) that is unrelated to the ASP-1929 PIT treatment",
            "criterions": [
                {
                    "exact_snippets": "Requiring future examinations or treatments within 4 weeks after an ASP-1929 PIT treatment exposing the patient to significant light (e.g., eye examinations, surgical procedures, endoscopy) that is unrelated to the ASP-1929 PIT treatment",
                    "criterion": "future examinations or treatments exposing the patient to significant light unrelated to ASP-1929 PIT treatment",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks after ASP-1929 PIT treatment"
                            }
                        },
                        {
                            "requirement_type": "necessity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}